Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2005-01-21
2008-10-07
Helms, Larry R. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S324000, C530S350000
Reexamination Certificate
active
07432357
ABSTRACT:
The invention provides modified antibodies directed against GD2 that have diminished complement fixation relative to antibody-dependent, cell-mediated cytotoxicity, which is maintained. The modified antibodies of the invention may be used in the treatment of tumors such as neuroblastoma, glioblastoma, melanoma, small-cell lung carcinoma, B-cell lymphoma, renal carcinoma, retinoblastoma, and other cancers of neuroectodermal origin.
REFERENCES:
patent: 4196265 (1980-04-01), Koprowski et al.
patent: 4676980 (1987-06-01), Segal et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 4975369 (1990-12-01), Beavers et al.
patent: 5082658 (1992-01-01), Palladino
patent: 5091513 (1992-02-01), Huston et al.
patent: 5114711 (1992-05-01), Bell et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5225538 (1993-07-01), Capon et al.
patent: 5225539 (1993-07-01), Winter
patent: 5258498 (1993-11-01), Huston et al.
patent: 5314995 (1994-05-01), Fell, Jr. et al.
patent: 5359035 (1994-10-01), Habermann
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5428130 (1995-06-01), Capon et al.
patent: 5514582 (1996-05-01), Capon et al.
patent: 5541087 (1996-07-01), Lo et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5601819 (1997-02-01), Wong et al.
patent: 5624821 (1997-04-01), Winter et al.
patent: 5645835 (1997-07-01), Fell, Jr. et al.
patent: 5650150 (1997-07-01), Gillies
patent: 5677425 (1997-10-01), Bodmer et al.
patent: 5679543 (1997-10-01), Lawlis
patent: 5712120 (1998-01-01), Rodriguez et al.
patent: 5723125 (1998-03-01), Chang et al.
patent: 5726044 (1998-03-01), Lo et al.
patent: 5770195 (1998-06-01), Hudziak et al.
patent: 5807715 (1998-09-01), Morrison et al.
patent: 5827516 (1998-10-01), Urban et al.
patent: 5827703 (1998-10-01), Debs et al.
patent: 5837821 (1998-11-01), Wu et al.
patent: 5843423 (1998-12-01), Lyman et al.
patent: 5888773 (1999-03-01), Jost et al.
patent: 5908626 (1999-06-01), Chang et al.
patent: 6100387 (2000-08-01), Herrmann et al.
patent: 6277375 (2001-08-01), Ward
patent: 6281010 (2001-08-01), Gao et al.
patent: 6284536 (2001-09-01), Morrison et al.
patent: 6291158 (2001-09-01), Winter et al.
patent: 6335176 (2002-01-01), Inglese et al.
patent: 6410008 (2002-06-01), Strom et al.
patent: 6475717 (2002-11-01), Enssle et al.
patent: 6617135 (2003-09-01), Gillies et al.
patent: 6627615 (2003-09-01), Debs et al.
patent: 6646113 (2003-11-01), Dreyfuss et al.
patent: 6838260 (2005-01-01), Gillies et al.
patent: 6972323 (2005-12-01), Serizawa et al.
patent: 2002/0037558 (2002-03-01), Lo et al.
patent: 2002/0081664 (2002-06-01), Lo et al.
patent: 2002/0114781 (2002-08-01), Strom et al.
patent: 2002/0146388 (2002-10-01), Gillies
patent: 2002/0147311 (2002-10-01), Gillies et al.
patent: 2002/0193570 (2002-12-01), Gillies et al.
patent: 2003/0003529 (2003-01-01), Bayer
patent: 2003/0044423 (2003-03-01), Gillies et al.
patent: 2003/0049227 (2003-03-01), Gillies et al.
patent: 2003/0103963 (2003-06-01), Cheung
patent: 2003/0105294 (2003-06-01), Gillies et al.
patent: 2003/0139365 (2003-07-01), Lo et al.
patent: 2003/0139575 (2003-07-01), Gillies
patent: 2003/0157054 (2003-08-01), Gillies et al.
patent: 2003/0166163 (2003-09-01), Gillies
patent: 2003/0166868 (2003-09-01), Presta et al.
patent: 2003/0166877 (2003-09-01), Gillies et al.
patent: 2004/0033210 (2004-02-01), Gillies
patent: 2004/0043457 (2004-03-01), Schumacher et al.
patent: 2004/0053366 (2004-03-01), Lo et al.
patent: 2004/0072299 (2004-04-01), Gillies et al.
patent: 2004/0082039 (2004-04-01), Gillies et al.
patent: 2004/0180035 (2004-09-01), Gillies et al.
patent: 2004/0180386 (2004-09-01), Carr et al.
patent: 2004/0203100 (2004-10-01), Gillies et al.
patent: 2005/0069521 (2005-03-01), Gillies et al.
patent: 21725/88 (1989-03-01), None
patent: 0 294 703 (1988-12-01), None
patent: 0 308 936 (1989-03-01), None
patent: 0 314 317 (1989-05-01), None
patent: 0 318 554 (1989-06-01), None
patent: 0 326 120 (1989-08-01), None
patent: 0 439 095 (1991-07-01), None
patent: 0 511 747 (1992-11-01), None
patent: 0 519 596 (1992-12-01), None
patent: 0 344 134 (1994-01-01), None
patent: 0 601 043 (1994-06-01), None
patent: 0 699 755 (1996-03-01), None
patent: 0 428 596 (1996-04-01), None
patent: 1 088 888 (2001-04-01), None
patent: 1 176 195 (2002-01-01), None
patent: 2 188 638 (1987-10-01), None
patent: WO 86/01533 (1986-03-01), None
patent: WO 88/09344 (1988-12-01), None
patent: WO 89/09620 (1989-10-01), None
patent: WO 91/04329 (1991-04-01), None
patent: WO 91/08298 (1991-06-01), None
patent: WO 91/13166 (1991-09-01), None
patent: WO 92/02240 (1992-02-01), None
patent: WO 92/08495 (1992-05-01), None
patent: WO 92/08801 (1992-05-01), None
patent: WO 92/10755 (1992-06-01), None
patent: WO 92/16562 (1992-10-01), None
patent: WO 93/03157 (1993-02-01), None
patent: WO 94/25609 (1994-11-01), None
patent: WO 95/05468 (1995-02-01), None
patent: WO 96/08570 (1996-03-01), None
patent: WO 97/00317 (1997-01-01), None
patent: WO 97/24137 (1997-07-01), None
patent: WO 97/30089 (1997-08-01), None
patent: WO 97/34631 (1997-09-01), None
patent: WO 98/52976 (1998-11-01), None
patent: WO 98/59244 (1998-12-01), None
patent: WO 99/03887 (1999-01-01), None
patent: WO 99/29732 (1999-06-01), None
patent: WO 00/01822 (2000-01-01), None
patent: WO 00/34317 (2000-06-01), None
patent: WO 02/079232 (2002-10-01), None
Skolnick et al. (Trends in Biotech., 18(1):34-39, 2000).
Colman et al (Research in Immunology 1994, 145:33-36).
Yu et al (J Clin Oncol. 1998, 16:2169-80).
Atlas of Immunology, Cruse and Lewis—p. 185.
Rudikoff et al (Proc. Natl. Acad. Sci. USA 1982 vol. 79 p. 1979).
Atlas of Immunology, Cruse and Lewis—p. 185, Dec. 2003, Second Edition.
Abaza et al., (1992), “Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization: Demonstration with Region 94-100 (Antigenic Site 3) of Myoglobin,”Journal of Protein Chemistry, 11(5):433-444.
Adkins et al., (1998), “Edrecolomab (Monoclonal Antibody 17-1A),”Drugs, 56(4):619-626.
Anderson et al., (1980), “Characterization of the Fc Receptor for IgG on a Human Macrophage Cell Line U937,”J. Immunol., 125(6):2735-41.
Angal et al., (1993), “A Single Amino Acid Substitution Abolishes the Heterogeneity of Chimeric Mouse/Human (IgG4) Antibody,”Molecular Immunology, 30(1):105-108.
Baici et al., (1980), “Kinetics of the Different Susceptibilities of the Four Human Immunoglobulin G Subclasses to Proteolysis by Human Lysosomal Elastase,”Scand. J. Immunol.12(1):41-50.
Batova et al., (1999), “The Ch14.18-GM-CSF Fusion Protein is Effective at Mediating Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity in Vitro,”Clinical Cancer Research, 5:4259-4263.
Batra et al., (1993), “Insertion of Constant Region Domains of Human IgG1 into CD4-PE40 Increases Its Plasma Half-Life,”Molecular Immunology, 30(4):379-386.
Becker et al., (1996), “An Antibody-Interleukin 2 Fusion Protein Overcomes Tumor Heterogeneity by Induction of a Cellular Immune Response,”Proc. Natl. Acad. Sci. USA, 93:7826-7831.
Becker et al., (1996), “Eradication of Human Hepatic and Pulmonary Melanoma Metastases in SCID Mice by Antibody-Interleukin 2 Fusion Proteins,”Proc. Natl. Acad. Sci. USA, 93:2702-2707.
Becker et al., (1996), “Long-Lived and Transferable Tumor Immunity in Mice after Targeted Interleukin-2 Therapy,”J. Clin. Invest., 98(12):2801-2804.
Becker et al., (1996), “T Cell-Mediated Eradication of Murine Metastatic Melanoma Induced by Targeted Interleukin-2 Therapy,”J. Exp. Med., 183(50):2361-2366.
Beutler et al., (1988), “Tumor Necrosis, Cachexia, Shock, and Inflammation: A Common Mediator,”Annual Rev. Biochem., 57:505-518.
Bitonti et al. (2004), “Pulmonary Delivery of an Erythropoietin Fc Fusion Protein in Non-Human Primates Through an Immunoglobulin Transport Pathway,”Pr
Goodwin & Procter LLP
Helms Larry R.
Merck Patent GmbH
Natarajan Meera
LandOfFree
Anti-cancer antibodies with reduced complement fixation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-cancer antibodies with reduced complement fixation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-cancer antibodies with reduced complement fixation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4011188